MaxCyte Strengthens Board with Cynthia Collins Appointment
Company Announcements

MaxCyte Strengthens Board with Cynthia Collins Appointment

MaxCyte (MXCT) has released an update.

MaxCyte, Inc. has appointed Cynthia Collins to its Board of Directors, enhancing its leadership with her extensive experience in cell therapy and genetic medicine. Collins, who has a notable background as CEO of several biotech companies, will serve on the board’s compensation committee. This appointment aligns with MaxCyte’s strategy to advance its cell engineering platform and support the development of next-generation cell-based therapies.

For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMaxCyte Weighs Delisting from AIM to Prioritize Nasdaq: Potential Benefits and Risks Ahead
TipRanks UK Auto-Generated NewsdeskMaxCyte’s Revenue Grows and Strategic Moves Unveiled
TipRanks UK Auto-Generated NewsdeskMaxCyte Files Quarterly Report, Highlights Financial Progress
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App